Our findings reveal significantly different risk profiles for immune-related neurologic complications in melanoma patients treated with PD-1 inhibitor monotherapy versus those treated with both PD-1 and CTLA-4 inhibitors. The gene discussed is CTLA4; the disease is melanoma.